Meta-analysis of Shugan Jieyu Capsule for depression in patients with coronary heart disease

ABSTRACT:

Introduction:

Shugan Jieyu Capsule (SGJYC) has been prescribed to treat primary and secondary depression; however, whether it can benefit depression of patients with coronary heart disease (CHD) remains controversial. This meta-analysis aimed to evaluate the efficacy and safety of SGJYC in treating depression in patients with CHD.

Patient concerns:

A total of 644 CHD patients with depression were selected from China National Knowledge Infrastructure, Wanfang, China Biomedical Database, MEDLINE, the Cochrane library from their inceptions until June, 2021.

Diagnosis:

All patients with CHD or coronary artery disease were confirmed to suffer from depression based on recognized criteria.

Intervention:

Patients were assigned randomly to receive SGJYC-based reg

SUBMITTER: Liu Z 

PROVIDER: S-EPMC10470748 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature